



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Mouse anti-MUC5AC, clone 2-12M1 (Monoclonal)

Clone no. 2-12M1

MONOSAN

Product name	Mouse anti-MUC5AC, clone 2-12M1 (Monoclonal)
Host	Mouse
Applications	ELISA, IHC-fr, IHC-P, WB
Species reactivity	human, mouse, monkey, cat, cow
Conjugate	-
Immunogen	mucin isolated from an ovarian cyst fluid
Isotype	IgG1
Clonality	Monoclonal
Clone number	2-12M1
Size	100 ug
Concentration	100 ug/ml
Format	-
Storage buffer	PBS with 0.02% sodium azide
Storage until expiry date	2-8°C

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES

Mouse anti-MUC5AC, clone 2-12M1 (Monoclonal)

Clone no. 2-12M1

MONOSAN

Additional info

2-12M1 recognizes the peptide core of gastric mucin M1/MUC5AC, and more specifically with the 'c' epitope amongst the a, b, c, d, e, f, g, and h protein core epitopes defined by Bara for M1. 2-12M1 and 45M1 both specifically react with epitopes located in the Cterminal cysteine rich part of the peptide core of gastric mucin (MUC5AC). MUC5AC is present in primary ovarian mucinous cancer and gastric cancer, but usually absent in colorectal adenocarcinoma, thus showing an expression pattern opposite to MUC2. AntiMUC5AC may be useful for differential identification of primary mucinous ovarian tumors from colon adenocarcinoma metastatic to the ovary. MUC5AC antibodies may also be useful for identification pancreatic carcinoma and pre-cancerous changes vs. normal pancreas.

References

1. Bara, J. et al., Cancer Res.46: 3983-3989 (1986)
2. Bara, J. et al., Biochem. J. 254: 185-193 (1988)
3. Bara, J. et al., Int. J. Cancer 47: 304-310 (1991)
4. Bara, J. et al., J. Immunol. Methods 149: 105-113 (1992)
5. Guyonnet Duperat V. et al., Biochem. J. 305: 211 219 (1995)

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES